https://mb.cision.com/Public/18595/3772832/988681b1eeadff20_800x800ar.png
** UCB and Veeva collaborate to advance the patient experience in clinical =
trials
------------------------------------------------------------
=C2=B7 Companies to work together to set a new standard for patient centric=
digital clinical trials
Brussels (Belgium), and Pleasanton, CA (US), 23 May 2023 (07:00 CET) - UCB,=
a global biopharmaceutical company, and Veeva Systems (NYSE: VEEV), today =
announced a collaboration that will focus on technology-driven solutions ai=
med at improving the patient experience and trial efficiency. The collabora=
tion will see UCB adopt Vevva ePRO and Veeva eConsent to provide a patient =
centric digital experience to study participants and will actively influenc=
e the strategic direction of these and other applications based on learning=
s. Together, Veeva and UCB aim to set a new industry standard for digital c=
linical trials with multiple applications that meet the unique needs of pat=
ients.=C2=A0
=E2=80=9CThe partnership between UCB and Veeva presents a significant oppor=
tunity to drive progress in clinical study execution,=E2=80=9D said Iris Lo=
ew-Friedrich, executive vice president and chief medical officer at UCB. =
=E2=80=9CBy delivering digital clinical trial, we reduce the burden on stud=
y participants and sites, improve trial accessibility ,to ensure we put pat=
ients at the heart of everything we do.=E2=80=9D
Veeva ePRO simplifies the design, management, and completion of electronic =
patient reported outcomes (ePRO), with seamless data flow among sponsors, s=
ites, and patients. Veeva eConsent simplifies the set-up, completion, and r=
eview of consent for patients, sites, and study teams. Both applications ar=
e available to patients through MyVeeva for Patients, which provides one po=
int of access for all their clinical trial actions, scheduling, and communi=
cations. Veeva ePRO and Veeva eConsent are part of Veeva Vault Clinical Sui=
te, a set of integrated capabilities that simplify the technology landscape=
of clinical trials for both clinical operations and clinical data manageme=
nt.=C2=A0
=E2=80=9CWe=E2=80=99re excited to partner with UCB to advance patient-centr=
ic digital trials,=E2=80=9D said Veeva CEO Peter Gassner. =E2=80=9CTheir in=
put will help advance Veeva=E2=80=99s approach to solutions that make digit=
al trials work even better for sponsors, sites, and patients.=E2=80=9D
Edwin Erckens, chief digital technology officer at UCB stated:=C2=A0=E2=80=
=9CUCB=E2=80=99s collaboration with Veeva is yet another proof point of our=
ongoing effort to drive digital business transformation. By leveraging our=
collective expertise, we can push the boundaries of what technology can ac=
hieve to improve the clinical trial process.=E2=80=9D=C2=A0
Financial details of the collaboration were not disclosed.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8,600 peopl=
e in approximately 40 countries, the company generated revenue of =E2=82=AC=
5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Foll=
ow us on Twitter: @UCB_news.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry=
. Committed to innovation, product excellence, and customer success, Veeva =
serves more than 1,000 customers, ranging from the world=E2=80=99s largest =
biopharmaceutical companies to emerging biotechs. As a Public Benefit Corpo=
ration, Veeva is committed to balancing the interests of all stakeholders, =
including customers, employees, shareholders, and the industries it serves.=
For more information, visit veeva.com.
For further information
Scott Fleming, R&D Communications (UCB), +447702777378, scott.fleming@ucb.c=
om
Antje Witte Investor Relations (UCB), +32.2.559.94.14, antje.witte@ucb.com
Laurent Schots, Corporate Communications (UCB), +32.2.559.92.64, laurent.sc=
hots@ucb.com
Jeremy Whittaker, Veeva Systems, +49-695-095-5486, jeremy.whittaker@veeva.c=
om
Forward looking statements
This press release may contain forward-looking statements including, withou=
t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =
=E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=
=E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim=
ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont=
inue=E2=80=9D and similar expressions. These forward-looking statements are=
based on current plans, estimates and beliefs of management. All statement=
s, other than statements of historical facts, are statements that could be =
deemed forward-looking statements, including estimates of revenues, operati=
ng margins, capital expenditures, cash, other financial information, expect=
ed legal, arbitration, political, regulatory or clinical results or practic=
es and other such estimates and results. By their nature, such forward-look=
ing statements are not guarantees of future performance and are subject to =
known and unknown risks, uncertainties and assumptions which might cause th=
e actual results, financial condition, performance or achievements of UCB, =
or industry results, to differ materially from those that may be expressed =
or implied by such forward-looking statements contained in this press relea=
se. Important factors that could result in such differences include: the gl=
obal spread and impact of COVID-19, changes in general economic, business a=
nd competitive conditions, the inability to obtain necessary regulatory app=
rovals or to obtain them on acceptable terms or within expected timing, cos=
ts associated with research and development, changes in the prospects for p=
roducts in the pipeline or under development by UCB, effects of future judi=
cial decisions or governmental investigations, safety, quality, data integr=
ity or manufacturing issues; potential or actual data security and data pri=
vacy breaches, or disruptions of our information technology systems, produc=
t liability claims, challenges to patent protection for products or product=
candidates, competition from other products including biosimilars, changes=
in laws or regulations, exchange rate fluctuations, changes or uncertainti=
es in tax laws or the administration of such laws, and hiring and retention=
of its employees. There is no guarantee that new product candidates will b=
e discovered or identified in the pipeline, will progress to product approv=
al or that new indications for existing products will be developed and appr=
oved. Movement from concept to commercial product is uncertain; preclinical=
results do not guarantee safety and efficacy of product candidates in huma=
ns. So far, the complexity of the human body cannot be reproduced in comput=
er models, cell culture systems or animal models. The length of the timing =
to complete clinical trials and to get regulatory approval for product mark=
eting has varied in the past and UCB expects similar unpredictability going=
forward. Products or potential products, which are the subject of partners=
hips, joint ventures or licensing collaborations may be subject to differen=
ces disputes between the partners or may prove to be not as safe, effective=
or commercially successful as UCB may have believed at the start of such p=
artnership. UCB=E2=80=99s efforts to acquire other products or companies an=
d to integrate the operations of such acquired companies may not be as succ=
essful as UCB may have believed at the moment of acquisition. Also, UCB or =
others could discover safety, side effects or manufacturing problems with i=
ts products and/or devices after they are marketed. The discovery of signif=
icant problems with a product similar to one of UCB=E2=80=99s products that=
implicate an entire class of products may have a material adverse effect o=
n sales of the entire class of affected products. Moreover, sales may be im=
pacted by international and domestic trends toward managed care and health =
care cost containment, including pricing pressure, political and public scr=
utiny, customer and prescriber patterns or practices, and the reimbursement=
policies imposed by third-party payers as well as legislation affecting bi=
opharmaceutical pricing and reimbursement activities and outcomes. Finally,=
a breakdown, cyberattack or information security breach could compromise t=
he confidentiality, integrity and availability of UCB=E2=80=99s data and sy=
stems.
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and it does not reflect any potenti=
al impact from the evolving COVID-19 pandemic, unless indicated otherwise. =
UCB is following the worldwide developments diligently to assess the financ=
ial significance of this pandemic to UCB. UCB expressly disclaims any duty =
to update any information contained in this press release, either to confir=
m the actual results or to report or reflect any change in its forward-look=
ing statements with regard thereto or any change in events, conditions or c=
ircumstances on which any such statement is based, unless such statement is=
required pursuant to applicable laws and regulations.
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
=C2=A0
GenericFile
UCB PR Veeva Collaboration May 23 2023 ENG (https://mb.cision.com/Public/18=
595/3772832/a56b6fab41e39093.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x136843x1x6868579x2400=
0x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01